Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2018 · 10-Q
Revenue—
Net Income-$2.27M-$2.27MN/M vs Q1 2017 EPS Diluted-$0.28-$0.28N/M vs Q1 2017 Operating Income-$2,260,000N/M Operating Cash Flow-$2,134,100N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end